antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E

Antibody-based therapies to fight cancer

Learn How AgilVax’s Technology Fights Cancer

AgilVax Discovers and Develops Targeted Antibody-Based Therapeutics

AgilVax’s lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is overexpressed on numerous tumor types including metastatic breast, colorectal, lung, pancreatic, hepatocellular cancers and glioblastoma.

By inhibiting the function of xCT, AX09, has the potential to enhance the effectiveness of current therapies, reduce metastatic spread, and make a dramatic improvement in patient survival.

Learn More
Download Factsheet

Latest News

View All News

Investors